Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

GlutathionevsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED6/39 cited
BPhase 3HUMAN-REVIEWED14/43 cited
Glutathione
Endogenous Tripeptide · Antioxidant
γ-Glu-Cys-GlyStructure
UbiquitousTissue distribution
GCL + GSBiosynthesisWang 2026Aiana 2026
IV · Oral · Inhaled
Sermorelin
GHRH 1-29 fragment · Short-acting
100–500 mcgPer doseMolteno 2013
Phase 3Evidence levelWalker 1994Molteno 2013
~12 minHalf-lifeMolteno 2013
SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter
Glutathione
Sermorelin
Primary target
Intracellular redox systems, glutathione peroxidase, glutathione transferase
Pituitary GHRH receptorWalker 1994
Pathway
Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
Yes — short pulse preserves feedback
Origin
Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025Hecht 2026
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development

02Dosage Protocols

Parameter
Glutathione
Sermorelin
Endogenous synthesis
Hepatic synthesis ~10 g/day (basal rate)
Tissue-specific; demand-driven upregulation via Nrf2 signaling.
Exogenous oral
250–1000 mg/day
Bioavailability limited; gastric hydrolysis reduces systemic uptake.
IV supplementation
600–1200 mg (research protocols)
Used in clinical oxidative stress and hepatic detoxification studies.
Precursor strategy
N-acetylcysteine (NAC) 600–1200 mg/day
Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.
Evidence basis
Animal mechanistic + human mechanistic
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Standard dose
100–500 mcg per injectionMolteno 2013
Frequency
Once daily, pre-sleep
Lower / starter dose
100 mcg per dose
Duration
8–12 weeks per cycle
Reconstitution
Bacteriostatic water
Timing
Pre-sleep, fasted preferred
Half-life
~12 min (plasma)Molteno 2013
Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

04Side Effects & Safety

Parameter
Glutathione
Sermorelin
Oral supplementation
GI discomfort, bloating (mild, dose-dependent)
IV administration
Rare hypersensitivity, infusion site reaction
Inhalation
Bronchospasm risk in asthma (rare)
Tumor metabolism
Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026
Injection site reaction
Mild erythema, transient pain
Flushing / headache
Common transient effect
IGF-1 elevation
Modest at standard doses
Cancer risk
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
Avoid
Glucose handling
Generally neutral
Absolute Contraindications
Glutathione
Sermorelin
  • ·Active malignancy
  • ·Pregnancy / breastfeeding
  • ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Glutathione
  • ·Active malignancy (theoretical cysteine supply risk)Hecht 2026
  • ·Severe asthma (inhaled formulations)
Sermorelin
  • ·Untreated diabetes

05Administration Protocol

Parameter
Glutathione
Sermorelin
1. Oral administration
Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Intravenous
Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.
SQ — abdomen or thigh. Rotate sites.
3. Inhaled formulations
Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.
Pre-sleep, fasted.
4. Precursor supplementation
N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Glutathione
— no documented stacks
Sermorelin
+ Ipamorelin
Strong
View Ipamorelin

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin
200–300 mcg SQ · pre-sleep
Ipamorelin
200–300 mcg SQ · same injection
Primary benefit
Pulsatile GH stimulation, recovery, body composition